Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Efficacy and safety of secukinumab in patients with active psoriatic arthritis at Week 16 and up to 52 weeks: Results from a Phase III, randomized, double-blind, placebo-controlled bridging study in China. Local targets link to admitted publications; unresolved targets remain external evidence.
Prevalence of psoriatic arthritis in Chinese population with psoriasis: A multicenter study conducted by experienced rheumatologists
10.1097/cm9.0000000000002683 · 2023 · External reference
Clinical characteristics of psoriatic arthritis in chinese patients: A cross-sectional study
10.1007/s40744-021-00384-y · 2021 · External reference
Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis
10.1097/cm9.0000000000001710 · 2021 · External reference
Pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies
10.3390/ijms241210305 · 2023 · External reference
Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety
10.1016/j.pharmthera.2021.107925 · 2022 · External reference
Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: Update on integrated pooled clinical trial and post-marketing surveillance data
10.2340/actadv.v102.563 · 2022 · External reference
Secukinumab: A review in psoriatic arthritis
10.1007/s40265-021-01476-3 · 2021 · External reference
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s0140-6736(15)61134-5 · 2015 · External reference
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: Results from a randomized, placebo-controlled trial (FUTURE 3)
10.1186/s13075-018-1551-x · 2018 · External reference
Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: Results from the FUTURE 4 study
10.1007/s40744-019-0163-5 · 2019 · External reference
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: Primary results from the randomised, double-blind, phase III FUTURE 5 study
10.1136/annrheumdis-2017-212687 · 2018 · External reference
Safety of secukinumab from 1 million patient-years of exposure: Experience from post-marketing setting and clinical trials
10.1007/s13555-024-01122-2 · 2024 · External reference
